|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gao L, Ye X, Ma RQ, Cheng HY, Han HJ, Cui
H, Wei LH and Chang XH: Low programmed cell death 5 expression is a
prognostic factor in ovarian cancer. Chin Med J. 128:1084–1090.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim MK, James J and Annunziata CM:
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce
apoptosis in ovarian cancer cells. BMC Cancer. 15:1962015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma R, Jiang T and Kang X: Circulating
microRNAs in cancer: Origin, function and application. J Exp Clin
Cancer Res. 31:382012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma Y, Zhang H, He X, Song H, Qiang Y, Li
Y, Gao J and Wang Z: miR-106a* inhibits the proliferation of renal
carcinoma cells by targeting IRS-2. Tumour Biol. 36:8389–8398.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yue B, Sun B, Liu C, Zhao S, Zhang D, Yu F
and Yan D: Long non-coding RNA Fer-1-like protein 4 suppresses
oncogenesis and exhibits prognostic value by associating with
miR-106a-5p in colon cancer. Cancer Sci. 106:1323–1332. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma HL, Wen XP, Zhang XZ, Wang XL, Zhao DL,
Che SM and Dang CX: miR-106a* inhibits the proliferation of
esophageal carcinoma cells by targeting CDK2-associated Cullin 1
(CACUL1). Cell Mol Biol. 61:56–62. 2015.
|
|
8
|
Yuan R, Wang G, Zhi Q, Chen H, Han Y, Wang
B, Kou Z, Hu H, Guo Z, Xue X, et al: Up-regulated circulating
miR-106a by DNA methylation promised a potential diagnostic and
prognostic marker for gastric cancer. Anticancer Agents Med Chem.
15:12015.
|
|
9
|
Xie X, Liu HT, Mei J, Ding FB, Xiao HB, Hu
FQ, Hu R and Wang MS: miR-106a promotes growth and metastasis of
non-small cell lung cancer by targeting PTEN. Int J Clin Exp
Pathol. 8:3827–3834. 2015.PubMed/NCBI
|
|
10
|
Macciò A and Madeddu C: Inflammation and
ovarian cancer. Cytokine. 58:133–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dijkgraaf EM, Welters MJ, Nortier JW, van
der Burg SH and Kroep JR: Interleukin-6/interleukin-6 receptor
pathway as a new therapy target in epithelial ovarian cancer. Curr
Pharm Des. 18:3816–3827. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Plante M, Rubin SC, Wong GY, Federici MG,
Finstad CL and Gastl GA: Interleukin-6 level in serum and ascites
as a prognostic factor in patients with epithelial ovarian cancer.
Cancer. 73:1882–1888. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scambia G, Testa U, Benedetti Panici P,
Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C
and Mancuso S: Prognostic significance of interleukin 6 serum
levels in patients with ovarian cancer. Br J Cancer. 71:354–356.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duan Z, Foster R, Bell DA, Mahoney J,
Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal
transducers and activators of transcription 3 pathway activation in
drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mihara M, Kasutani K, Okazaki M, Nakamura
A, Kawai S, Sugimoto M, Matsumoto Y and Ohsugi Y: Tocilizumab
inhibits signal transduction mediated by both mIL-6R and sIL-6R,
but not by the receptors of other members of IL-6 cytokine family.
Int Immunopharmacol. 5:1731–1740. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shinriki S, Jono H, Ota K, Ueda M, Kudo M,
Ota T, Oike Y, Endo M, Ibusuki M, Hiraki A, et al: Humanized
anti-interleukin-6 receptor antibody suppresses tumor angiogenesis
and in vivo growth of human oral squamous cell carcinoma. Clin
Cancer Res. 15:5426–5434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishimoto N, Kanakura Y, Aozasa K, Johkoh
T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K,
et al: Humanized anti-interleukin-6 receptor antibody treatment of
multicentric Castleman disease. Blood. 106:2627–2632. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishimoto N, Hashimoto J, Miyasaka N,
Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D and
Kishimoto T: Study of active controlled monotherapy used for
rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of
clinical and radiographic benefit from an x ray reader-blinded
randomised controlled trial of tocilizumab. Ann Rheum Dis.
66:1162–1167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Isobe A, Sawada K, Kinose Y, Ohyagi-Hara
C, Nakatsuka E, Makino H, Ogura T, Mizuno T, Suzuki N, Morii E, et
al: Interleukin 6 receptor is an independent prognostic factor and
a potential therapeutic target of ovarian cancer. PLoS One.
10:e01180802015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ando K, Takahashi F, Kato M, Kaneko N, Doi
T, Ohe Y, Koizumi F, Nishio K and Takahashi K: Tocilizumab, a
proposed therapy for the cachexia of Interleukin6-expressing lung
cancer. PLoS One. 9:e1024362014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ando K, Takahashi F, Motojima S, Nakashima
K, Kaneko N, Hoshi K and Takahashi K: Possible role for
tocilizumab, an anti-interleukin-6 receptor antibody, in treating
cancer cachexia. J Clin Oncol. 31:e69–e72. 2013. View Article : Google Scholar
|
|
22
|
Berti A, Boccalatte F, Sabbadini MG and
Dagna L: Assessment of tocilizumab in the treatment of cancer
cachexia. J Clin Oncol. 31:29702013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirata H, Tetsumoto S, Kijima T, Kida H,
Kumagai T, Takahashi R, Otani Y, Inoue K, Kuhara H, Shimada K, et
al: Favorable responses to tocilizumab in two patients with
cancer-related cachexia. J Pain Symptom Manage. 46:e9–e13. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim NH, Kim SK, Kim DS, Zhang D, Park JA,
Yi H, Kim JS and Shin HC: Anti-proliferative action of
IL-6R-targeted antibody tocilizumab for non-small cell lung cancer
cells. Oncol Lett. 9:2283–2288. 2015.PubMed/NCBI
|
|
25
|
Yamagata K, Shimojo N, Ito H, Ijima J,
Hasegawa S, Yanagawa T, Mizutani T and Bukawa H: Severe pulmonary
suppuration with infection-induced systemic inflammatory response
syndrome following tongue cancer surgery in a patient undergoing
tocilizumab therapy for rheumatoid arthritis. Case Rep Dent.
2014:6490862014.PubMed/NCBI
|
|
26
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen W, Huang L, Hao C, Zeng W, Luo X, Li
X, Zhou L, Jiang S, Chen Z and He Y: MicroRNA-155 promotes
apoptosis in SKOV3, A2780, and primary cultured ovarian cancer
cells. Tumour Biol. Jan 15–2016.Epub ahead of print.
|
|
28
|
Chen W, Zeng W, Li X, Xiong W, Zhang M,
Huang Y, Zhou L and Jiang S: MicroRNA-509-3p increases the
sensitivity of epithelial ovarian cancer cells to cisplatin-induced
apoptosis. Pharmacogenomics. 17:187–197. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fan JY, Yang Y, Xie JY, Lu YL, Shi K and
Huang YQ: MicroRNA-144 mediates metabolic shift in ovarian cancer
cells by directly targeting Glut1. Tumour Biol. 37:6855–6860. 2016.
View Article : Google Scholar
|
|
30
|
Fu X, Cui Y, Yang S, Xu Y and Zhang Z:
MicroRNA-613 inhibited ovarian cancer cell proliferation and
invasion by regulating KRAS. Tumour Biol. 37:6477–6483. 2016.In
Chinese. View Article : Google Scholar
|
|
31
|
Guo P, Peng D, Xiong X and Zhang S:
Expression of microRNA-100 and its correlation with drug resistance
in human ovarian cancer SKOV3/DDP cells. Nan Fang Yi Ke Da Xue Xue
Bao. 35:1624–1627. 2015.In Chinese. PubMed/NCBI
|
|
32
|
Langhe R: microRNA and ovarian cancer. Adv
Exp Med Biol. 889:119–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang H, Jiang Z, Xie G and Lu Y: Serum
microRNA-145 as a novel biomarker in human ovarian cancer. Tumour
Biol. 36:5305–5313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu X and Li G: MicroRNA-133b inhibits
proliferation and invasion of ovarian cancer cells through Akt and
Erk1/2 inactivation by targeting epidermal growth factor receptor.
Int J Clin Exp Pathol. 8:10605–10614. 2015.PubMed/NCBI
|
|
35
|
Luo P, Fei J, Zhou J and Zhang W:
microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3
cells. Oncol Lett. 9:2225–2229. 2015.PubMed/NCBI
|
|
36
|
Pal MK, Jaiswar SP, Dwivedi VN, Tripathi
AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising
potential biomarker for diagnosis and prognosis of ovarian cancer.
Cancer Biol Med. 12:328–341. 2015.
|
|
37
|
Quitadamo A, Tian L, Hall B and Shi X: An
integrated network of microRNA and gene expression in ovarian
cancer. BMC Bioinformatics. 16(Suppl 5): S52015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shariati-Kohbanani M, Zare-Bidaki M,
Taghavi MM, Taghipour Z, Shabanizadeh A, Kennedy D, Dahim H,
Salahshoor MR, Jalili C and Kazemi Arababadi M: DNA Methylation and
microRNA patterns are in association with the expression of BRCA1
in ovarian cancer. Cell Mol Biol. 62:16–23. 2016.PubMed/NCBI
|
|
39
|
Sun KX, Jiao JW, Chen S, Liu BL and Zhao
Y: MicroRNA-186 induces sensitivity of ovarian cancer cells to
paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res.
8:802015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang ZH and Xu CJ: Research progress of
microRNA in early detection of ovarian cancer. Chin Med J.
128:3363–3370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu DD, Li XS, Meng XN, Yan J and Zong ZH:
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells
by targeting ABCB1. Tumour Biol. Feb 5–2016.Epub ahead of
print.
|
|
42
|
Ying HC, Xu HY, Lv J, Ying TS and Yang Q:
MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J
Gynaecol Oncol. 36:16–20. 2015.PubMed/NCBI
|
|
43
|
Catela Ivkovic T, Aralica G, Cacev T,
Loncar B and Kapitanovic S: miR-106a overexpression and pRB
downregulation in sporadic colorectal cancer. Exp Mol Pathol.
94:148–154. 2013. View Article : Google Scholar
|
|
44
|
Díaz R, Silva J, García JM, Lorenzo Y,
García V, Peña C, Rodríguez R, Muñoz C, García F, Bonilla F, et al:
Deregulated expression of miR-106a predicts survival in human colon
cancer patients. Genes Chromosomes Cancer. 47:794–802. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fang Y, Shen H, Li H, Cao Y, Qin R, Long
L, Zhu X, Xie C and Xu W: miR-106a confers cisplatin resistance by
regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim
Biophys Sin. 45:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hou X, Zhang M and Qiao H: Diagnostic
significance of miR-106a in gastric cancer. Int J Clin Exp Pathol.
8:13096–13101. 2015.
|
|
47
|
Huh JH, Kim TH, Kim K, Song JA, Jung YJ,
Jeong JY, Lee MJ, Kim YK, Lee DH and An HJ: Dysregulation of
miR-106a and miR-591 confers paclitaxel resistance to ovarian
cancer. Br J Cancer. 109:452–461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Koga Y, Yamazaki N, Yamamoto Y, Yamamoto
S, Saito N, Kakugawa Y, Otake Y, Matsumoto M and Matsumura Y: Fecal
miR-106a is a useful marker for colorectal cancer patients with
false-negative results in immunochemical fecal occult blood test.
Cancer Epidemiol Biomarkers Prev. 22:1844–1852. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li P, Xu Q, Zhang D, Li X, Han L, Lei J,
Duan W, Ma Q, Wu Z and Wang Z: Upregulated miR-106a plays an
oncogenic role in pancreatic cancer. FEBS Lett. 588:705–712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rao YM, Shi HR, Ji M and Chen CH: MiR-106a
targets Mcl-1 to suppress cisplatin resistance of ovarian cancer
A2780 cells. J Huazhong Univ Sci Technolog Med Sci. 33:567–572.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schee K, Boye K, Abrahamsen TW, Fodstad Ø
and Flatmark K: Clinical relevance of microRNA miR-21, miR-31,
miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC
Cancer. 12:5052012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C,
Quan L, Bai J and Xu N: miR-106a is frequently upregulated in
gastric cancer and inhibits the extrinsic apoptotic pathway by
targeting FAS. Mol Carcinog. 52:634–646. 2013. View Article : Google Scholar
|
|
53
|
Zhang L, Meng L, Fan Z, Liu B, Pei Y and
Zhao Z: Expression of plasma miR-106a in colorectal cancer and its
clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 34:354–357.
2014.In Chinese. PubMed/NCBI
|
